Our finding of worse treatment outcomes when olaparib was combined with clodronate in an immune-competent host, however, suggested that in the specific setting of PARP inhibition, TAMs did not promote tumor growth but contributed to the anti-tumor response with olaparib. This evidence concerns the gene PARP1 and neoplasm.